Study of STIM1 Membrane Expression

Study of STIM1 Membrane Expression During Autoimmune Diseases

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04978948

Acronym

STIMEX

Enrollment

670

Registered

2021-07-27

Start date

2021-05-11

Completion date

2027-05-01

Last updated

2026-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Diseases

Keywords

autoimmune diseases

Brief summary

The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM. This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of one of the autoimmune diseases

Exclusion criteria

* Treatment with rituximab in the previous 12 months

Design outcomes

Primary

Measure	Time frame	Description
level of STIM1-PM	Day 0	Membrane expression level of STIM1-PM on the surface of immune cells, measured by flow cytometry

Secondary

Measure	Time frame	Description
correlation between STIM1 expression and Clinical Score	Day 0	Study of correlation between STIM1 expression on different cells and clinical scores of different autoimmune diseases or treatments received

Countries

France

Contacts

CONTACTDivi Cornec

divi.cornec@chu-brest.fr02 98 22 33 33

Outcome results